Used in the treatment of various cancers, particularly relapsed or refractory classical Hodgkin lymphoma. It functions by blocking the PD-1 receptor on T-cells, thereby enhancing the immune system’s ability to detect and destroy cancer cells. Shows promising clinical activity in other hematologic malignancies and solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma. Administered intravenously, it is part of immunotherapy regimens aimed at achieving durable responses in patients who have failed prior therapies. Its humanized design reduces immunogenicity, supporting long-term treatment with manageable safety profile.